H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares following ...

HC Wainwright reissued their buy rating on shares of Harmony Biosciences (NASDAQ:HRMY – Free Report) in a report published on ...

H.C. Wainwright analyst Matthew Keller keeps a Buy rating on FibroGen (FGEN) with a $10 price target after the company announced the sale of ...

Arcus Biosciences (NYSE:RCUS – Get Free Report) had its price target dropped by equities researchers at HC Wainwright from ...

H.C. Wainwright adjusted its price target for Largo Resources Ltd. (NASDAQ:LGO) to $3.70, down from the previous $4.20, while maintaining a "Buy" rating on the stock. The firm's decision follows Largo ...

H.C. Wainwright reiterated a Buy rating and a price target of $18.00 on Enanta Pharmaceuticals (NASDAQ:ENTA) shares, significantly above the current price of $4.90. The stock is trading near its ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (LSE:0VRQ) with a Buy recommendation. There are 575 funds or institutions reporting positions ...

In 2024 H.C. Wainwright also held the top position in PlacementTracker's Market League Tables for At-the-Market (ATM) Offerings representing 72 transactions. In addition to presently serving as ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (BRSE:1CG) with a Buy recommendation. There are 575 funds or institutions reporting positions ...